Tumor stem cell niches: A new functional framework for the action of anticancer drugs

被引:24
作者
Baguley, Bruce C. [1 ]
机构
[1] Univ Auckland, Auckland Canc Soc Res Ctr, Fac Med & Hlth Sci, Auckland, New Zealand
关键词
stem cells; stroma; niche; cytokinetics; survival factors; cytotoxic drugs; signal transduction inhibitors; vascular disrupting agents;
D O I
10.2174/157489206775246494
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Newer treatments of advanced human cancer increasingly rely on combinations of drugs that have quite different actions yet unexpectedly potentiate each other's effects. Recent research in stem cell biology suggests a model for tumors in which tumor growth is governed by the generation of cells from tumor cell niches rather than from the population as a whole. Each niche contains a population of tumor stem cells supported by a closely associated vascular bed comprising mesenchyme-derived cells and an extracellular matrix. Division of tumor stem cells is asymmetric in the sense that some daughter cells are always retained within the niche while others leave the niche to proliferate further and eventually die. One important potential difference between normal and tumor stem cell niches is that while most normal stem cells are in a non-proliferating or Go-state, tumor stem cells are continuously in cycle. Combinations of cytotoxic drugs and antagonists of survival factors to reduce the stem cell population may require the addition of vascular disrupting agents to compromise the function of the tumor cell niche. As well as providing opportunities for new drug discovery, this model of tumor growth also presents challenges as to how the contributions of individual drugs in a combination might be assessed in individual patients.Newer treatments of advanced human cancer increasingly rely on combinations of drugs that have quite different actions yet unexpectedly potentiate each other's effects. Recent research in stem cell biology suggests a model for tumors in which tumor growth is governed by the generation of cells from tumor cell niches rather than from the population as a whole. Each niche contains a population of tumor stem cells supported by a closely associated vascular bed comprising mesenchyme-derived cells and an extracellular matrix. Division of tumor stem cells is asymmetric in the sense that some daughter cells are always retained within the niche while others leave the niche to proliferate further and eventually die. One important potential difference between normal and tumor stem cell niches is that while most normal stem cells are in a non-proliferating or Go-state, tumor stem cells are continuously in cycle. Combinations of cytotoxic drugs and antagonists of survival factors to reduce the stem cell population may require the addition of vascular disrupting agents to compromise the function of the tumor cell niche. As well as providing opportunities for new drug discovery, this model of tumor growth also presents challenges as to how the contributions of individual drugs in a combination might be assessed in individual patients.Newer treatments of advanced human cancer increasingly rely on combinations of drugs that have quite different actions yet unexpectedly potentiate each other's effects. Recent research in stem cell biology suggests a model for tumors in which tumor growth is governed by the generation of cells from tumor cell niches rather than from the population as a whole. Each niche contains a population of tumor stem cells supported by a closely associated vascular bed comprising mesenchyme-derived cells and an extracellular matrix. Division of tumor stem cells is asymmetric in the sense that some daughter cells are always retained within the niche while others leave the niche to proliferate further and eventually die. One important potential difference between normal and tumor stem cell niches is that while most normal stem cells are in a non-proliferating or Go-state, tumor stem cells are continuously in cycle. Cmbinations of cytotoxic drugs and antagonists of survival factors to reduce the stem cell population may require the addition of vascular disrupting agents to compromise the function of the tumor cell niche. As well as providing opportunities for new drug discovery, this model of tumor growth also presents challenges as to how the contributions of individual drugs in a combination might be assessed in individual patients.Newer treatments of advanced human cancer increasingly rely on combinations of drugs that have quite different actions yet unexpectedly potentiate each other's effects. Recent research in stem cell biology suggests a model for tumors in which tumor growth is governed by the generation of cells from tumor cell niches rather than from the population as a whole. Each niche contains a population of tumor stem cells supported by a closely associated vascular bed comprising mesenchyme-derived cells and an extracellular matrix. Division of tumor stem cells is asymmetric in the sense that some daughter cells are always retained within the niche while others leave the niche to proliferate further and eventually die. One important potential difference between normal and tumor stem cell niches is that while most normal stem cells are in a non-proliferating or Go-state, tumor stem cells are continuously in cycle. Combinations of cytotoxic drugs and antagonists of survival factors to reduce the stem cell population may require the addition of vascular disrupting agents to compromise the function of the tumor cell niche. As well as providing opportunities for new drug discovery, this model of tumor growth also presents challenges as to how the contributions of individual drugs in a combination might be assessed in individual patients.
引用
收藏
页码:121 / 127
页数:7
相关论文
共 52 条
[1]   Multipotent nestin-positive, keratin-negative hair-follicle bulge stem cells can form neurons [J].
Amoh, Y ;
Li, L ;
Katsuoka, K ;
Penman, S ;
Hoffman, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (15) :5530-5534
[2]   Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases [J].
Baguley, BC ;
Marshall, ES ;
Holdaway, IM ;
Rewcastle, GW ;
Denny, WA .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (07) :1086-1090
[3]   In vitro modelling of human tumour behaviour in drug discovery programmes [J].
Baguley, BC ;
Marshall, ES .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (06) :794-801
[4]  
BAGULEY BC, 2000, Patent No. 506060
[5]   A mathematical model for analysis of the cell cycle in cell lines derived from human tumors [J].
Basse, B ;
Baguley, BC ;
Marshall, ES ;
Joseph, WR ;
van Brunt, B ;
Wake, G ;
Wall, DJN .
JOURNAL OF MATHEMATICAL BIOLOGY, 2003, 47 (04) :295-312
[6]   Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells [J].
Berezovskaya, O ;
Schimmer, AD ;
Glinskii, AB ;
Pinilla, C ;
Hoffman, RM ;
Reed, JC ;
Glinsky, GV .
CANCER RESEARCH, 2005, 65 (06) :2378-2386
[7]   Medulloblastoma growth inhibition by Hedgehog pathway blockade [J].
Berman, DM ;
Karhadkar, SS ;
Hallahan, AR ;
Pritchard, JI ;
Eberhart, CG ;
Watkins, DN ;
Chen, JK ;
Cooper, MK ;
Taipale, J ;
Olson, JM ;
Beachy, PA .
SCIENCE, 2002, 297 (5586) :1559-1561
[8]   Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1 [J].
Bigelow, RLH ;
Chari, NS ;
Undén, AB ;
Spurgers, KB ;
Lee, SJ ;
Roop, DR ;
Toftgård, R ;
McDonnell, TJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (02) :1197-1205
[9]  
BRADBURY RH, 2005, Patent No. 20050165035A1
[10]   Gastrointestinal stem cells [J].
Brittan, M ;
Wright, NA .
JOURNAL OF PATHOLOGY, 2002, 197 (04) :492-509